Large sum of $1.3 billion obtained through venture funding by Frazier Life Sciences marks the successful closure of their investment round
Frazier Life Sciences (FLS), a leading life sciences venture capital firm, has announced the closing of its latest fund, FLS XII, with over $1.3 billion in capital commitments. This fund will primarily focus on investing in early-stage private biopharmaceutical companies developing novel therapeutics to address significant medical needs [1][2][4].
With a team of seven investment partners and over 35 investment professionals, operating professionals, and senior advisors, FLS brings a wealth of experience across therapeutic areas and company stages [3]. Patrick Heron, the Managing Partner at FLS, leads the firm's strategy of supporting pioneering companies and exceptional entrepreneurs advancing therapeutic programs with the potential to meet these important health challenges [6].
Since 2016, FLS has raised over $3.6 billion across five dedicated venture funds [5]. Notable investments include Alpine Immune Sciences, which was acquired by Vertex, and Amunix Pharmaceuticals, which was acquired by Sanofi. The firm has also been instrumental in the creation of 25 new companies since 2020 [1][2][5].
FLS takes a hands-on, collaborative approach, working closely with entrepreneurs to advance therapeutic programs with the potential to address significant medical needs. The firm has received strong support from both longstanding and new limited partners for FLS XII [2].
In addition to FLS XII, FLS has raised more than $1.7 billion in long-only public funds since 2021 [7]. The firm's extensive portfolio includes investments in Arcutis Biotherapeutics, Mirum Pharmaceuticals, NewAmsterdam Pharma, and Tarsus Pharmaceuticals [8].
As FLS moves forward with FLS XII, the firm remains committed to its mission of investing in innovative drug development to address significant unmet medical needs [1][2][5]. With its experienced team and substantial resources, FLS is well-positioned to support the next generation of life sciences companies.
- While Frazier Life Sciences (FLS) primarily invests in biopharmaceutical companies, the firm has also expanded into other areas, acknowledging the importance of screening opportunities in health-and-wellness, science, and finance.
- In addition to supporting life sciences startups in the healthcare sector, FLS has ventured into investing in other industries, such as finance and investing, recognizing the potential synergies these connections could bring to their ongoing mission.
